Pharmacokinetics of anti-VEGF drugs suggest reinjection between 4 weeks and 8 weeks

VIENNA — Calculation of the half-life of anti-VEGF drugs supports reinjection intervals between 4 weeks and 8 weeks, according to studies presented by one speaker. “We developed an enzyme ELISA test to determine the concentration of unbound bevacizumab and ranibizumab in the anterior chamber at different time points after injection and used it in a series of prospective trials,” Carsten H. Meyer, MD, said at the Advanced Retinal Therapy meeting.

Full Story →